A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2-DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS

Go Back to All Clinical Trials

A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2-DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Clostridium Difficile
Age: Between 65 Year(s) - 110 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Healthy adult
2. 65 years of age or older
3. Agree to comply with all study requirements

You may not be eligible for this study if the following are true:

1. History of severe reaction associated with a vaccine
2. Immunocompromised individuals with known or suspected Immunodeficiency
3. Previously received an investigational Clostridioides difficile (C. diff) vaccine or C. diff monoclonal antibody therapy
4. Have had a confirmed episode of C. diff infection

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies